CTI BioPharma Corp. (CTIC)
Jun 26, 2023 - CTIC was delisted (reason: acquired by Sobi)
9.09
0.00 (0.00%)
Inactive · Last trade price
on Jun 23, 2023
Company Description
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States.
It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis.
It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; S*BIO Pte Ltd.; and Baxalta.
The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014.
CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington.
CTI BioPharma Corp.
Country | United States |
Founded | 1991 |
IPO Date | Mar 21, 1997 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 127 |
CEO | Dr. Adam R. Craig M.B.A., M.D., Ph.D. |
Contact Details
Address: 3101 Western Avenue, Suite 800 Seattle, Washington 98121 | |
Phone | (206) 282-7100 |
Website | ctibiopharma.com |
Stock Details
Ticker Symbol | CTIC |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0000891293 |
CUSIP Number | 12648L601 |
ISIN Number | US12648L6011 |
Employer ID | 91-1533912 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Adam R. Craig M.B.A., M.D., Ph.D. | President, Chief Executive Officer, Interim Chief Medical Officer and Director |
David H. Kirske | Executive Vice President, Chief Financial Officer and Secretary |
Ed Bell | Senior Director of Investor Relations |
James K. Fong | Executive Vice President and Chief Commercial Officer |
Bruce K. Bennett Jr. | Senior Vice President Global Pharmaceutical Operations |
John P. Volpone | Executive Vice President and Chief of Staff |
Dr. Jennifer A. Smith | Senior Vice President of Biometrics |